Leerink Partners Maintains Market Perform on Myriad Genetics, Raises Price Target to $8
Leerink Partners analyst Puneet Souda maintains Myriad Genetics (NASDAQ:MYGN) with a Market Perform and raises the price target from $5 to $8.
Share
Why It Matters
An expert raised their price goal for Myriad Genetics from $5 to $8. This suggests they see the company worth more, but they still think the stock is fairly priced right now.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.